S-Adenosyl-L-Methionine Cas 29908-03-0

Comprehensive Guide to S-Adenosyl-L-Methionine (SAMe) CAS 29908-03-0

Table of Contents

• Product Overview & Specifications
• Key Applications & Benefits
• Usage Guidelines & Best Practices
• Industry Case Studies
• Verified Client Success Stories
• Contact Supplier & Request Quote

Product Specifications: SAMe CAS 29908-03-0

Primary Applications & Therapeutic Benefits

Clinical Applications

• Depression management: SAMe boosts serotonin/dopamine synthesis
• Osteoarthritis support: Stimulates cartilage production
• Liver health: Promotes glutathione production for detoxification

Research Applications

• Epigenetic studies: Key methyl group donor in DNA methylation
• Neurodegenerative disease research: Alzheimer’s/Parkinson’s models

Optimal Usage Protocols

Dosage Recommendations

Stability Considerations

• Use pH-stabilized formulations below 40°C
• Combine with antioxidants for extended shelf life

Documented Clinical Outcomes

Hepatology Study (2023)

• 68% reduction in ALT levels in NAFLD patients
• 600 mg/day SAMe + standard care for 24 weeks

Rheumatology Trial (2022)

• 42% pain reduction in knee osteoarthritis
• 1200 mg/day oral SAMe vs placebo

Verified Client Implementations

Pharma Manufacturer: Vitalis Therapeutics

• Application: SAMe-based antidepressant formulation
• Outcome: 30% faster onset vs conventional SSRIs
• Volume: 200kg/month GMP-grade SAMe

Research Institute: NeuroCure Labs

• Application: Parkinson’s disease mechanism study
• Result: Identified 3 novel methylation targets
• Usage: 50g/week for 18-month study

Supplier Inquiry & Technical Support

Request customized SAMe solutions:

• Email: info@vivalr.com
• Phone: (86) 15866781826

Specify requirements:

• Required quantity (grams to kilograms)
• Application purpose (clinical/research)
• Preferred formulation (powder/tablet/injectable)